Prajna Lalitha1, Catherine Q Sun2, N Venkatesh Prajna1, Rajarathinam Karpagam1, Manoharan Geetha1, Kieran S O'Brien2, Vicky Cevallos2, Stephen D McLeod3, Nisha R Acharya3, Thomas M Lietman4. 1. Aravind Eye Care System, Madurai, India. 2. F.I. Proctor Foundation, University of California San Francisco, San Francisco, California. 3. F.I. Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California. 4. F.I. Proctor Foundation, University of California San Francisco, San Francisco, California; Department of Ophthalmology, University of California San Francisco, San Francisco, California; Department of Epidemiology & Biostatistics, University of California San Francisco, San Francisco, California. Electronic address: tom.lietman@ucsf.edu.
Abstract
PURPOSE: To describe the minimum inhibitory concentration (MIC) of fungal isolates to natamycin and voriconazole, and to compare these MICs to previous ocular susceptibility studies. DESIGN: Experimental laboratory study using isolates from a randomized clinical trial. METHODS: The Mycotic Ulcer Treatment Trial I was a randomized, double-masked, multicenter trial comparing topical natamycin and voriconazole for fungal keratitis treatment. Susceptibility testing to natamycin and voriconazole were performed according to Clinical and Laboratory Standards Institute methods. The relationship between organism and MIC was assessed. A literature review was performed to compare results to previous ocular susceptibility studies. RESULTS: Of the 323 patients enrolled in the trial, MICs were available for 221 (68%). Fusarium (n = 126) and Aspergillus species (n = 52) were the most commonly isolated organisms. MICs to natamycin and voriconazole were significantly different across all genera (P < .001). The MIC median (MIC50) and 90th percentile (MIC90) for natamycin were equal to or higher than voriconazole for all organisms except Curvularia species. Compared to other organisms, Fusarium species isolates had the highest MICs to voriconazole and Aspergillus flavus isolates had the highest MICs to natamycin. Our results were similar to previous reports except that the voriconazole MIC90 against Aspergillus species was 2-fold higher and the natamycin MIC90 against Aspergillus fumigatus was 4-fold higher in our study. CONCLUSION: In this large susceptibility study, Fusarium isolates were least susceptible to voriconazole and A flavus isolates were least susceptible to natamycin when compared to other filamentous fungi. In the future, susceptibility testing may help guide therapy if performed in a timely manner.
RCT Entities:
PURPOSE: To describe the minimum inhibitory concentration (MIC) of fungal isolates to natamycin and voriconazole, and to compare these MICs to previous ocular susceptibility studies. DESIGN: Experimental laboratory study using isolates from a randomized clinical trial. METHODS: The Mycotic Ulcer Treatment Trial I was a randomized, double-masked, multicenter trial comparing topical natamycin and voriconazole for fungal keratitis treatment. Susceptibility testing to natamycin and voriconazole were performed according to Clinical and Laboratory Standards Institute methods. The relationship between organism and MIC was assessed. A literature review was performed to compare results to previous ocular susceptibility studies. RESULTS: Of the 323 patients enrolled in the trial, MICs were available for 221 (68%). Fusarium (n = 126) and Aspergillus species (n = 52) were the most commonly isolated organisms. MICs to natamycin and voriconazole were significantly different across all genera (P < .001). The MIC median (MIC50) and 90th percentile (MIC90) for natamycin were equal to or higher than voriconazole for all organisms except Curvularia species. Compared to other organisms, Fusarium species isolates had the highest MICs to voriconazole and Aspergillus flavus isolates had the highest MICs to natamycin. Our results were similar to previous reports except that the voriconazole MIC90 against Aspergillus species was 2-fold higher and the natamycin MIC90 against Aspergillus fumigatus was 4-fold higher in our study. CONCLUSION: In this large susceptibility study, Fusarium isolates were least susceptible to voriconazole and A flavus isolates were least susceptible to natamycin when compared to other filamentous fungi. In the future, susceptibility testing may help guide therapy if performed in a timely manner.
Authors: Elmer Y Tu; David L McCartney; Richard F Beatty; Kathryn L Springer; Jaime Levy; Deepak Edward Journal: Am J Ophthalmol Date: 2006-12-08 Impact factor: 5.258
Authors: M A Pfaller; S A Messer; L Boyken; C Rice; S Tendolkar; R J Hollis; D J Diekema Journal: J Clin Microbiol Date: 2008-06-18 Impact factor: 5.948
Authors: Juan Luis Rodriguez-Tudela; Laura Alcazar-Fuoli; Emilia Mellado; Ana Alastruey-Izquierdo; Araceli Monzon; Manuel Cuenca-Estrella Journal: Antimicrob Agents Chemother Date: 2008-05-12 Impact factor: 5.191
Authors: Prajna Lalitha; Brett L Shapiro; Muthiah Srinivasan; Namperumalsamy Venkatesh Prajna; Nisha R Acharya; Annette W Fothergill; Jazmin Ruiz; Jaya D Chidambaram; Kathryn J Maxey; Kevin C Hong; Stephen D McLeod; Thomas M Lietman Journal: Arch Ophthalmol Date: 2007-06
Authors: N Venkatesh Prajna; Tiruvengada Krishnan; Revathi Rajaraman; Sushila Patel; Muthiah Srinivasan; Manoranjan Das; Kathryn J Ray; Kieran S O'Brien; Catherine E Oldenburg; Stephen D McLeod; Michael E Zegans; Travis C Porco; Nisha R Acharya; Thomas M Lietman; Jennifer Rose-Nussbaumer Journal: JAMA Ophthalmol Date: 2016-12-01 Impact factor: 7.389
Authors: Catherine Q Sun; Prajna Lalitha; N Venkatesh Prajna; Rajarathinam Karpagam; Manoharan Geetha; Kieran S O'Brien; Catherine E Oldenburg; Kathryn J Ray; Stephen D McLeod; Nisha R Acharya; Thomas M Lietman Journal: Ophthalmology Date: 2014-04-16 Impact factor: 12.079
Authors: Catherine E Oldenburg; N Venkatesh Prajna; Tiruvengada Krishnan; Revathi Rajaraman; Muthiah Srinivasan; Kathryn J Ray; Kieran S O'Brien; M Maria Glymour; Travis C Porco; Nisha R Acharya; Jennifer Rose-Nussbaumer; Thomas M Lietman Journal: Ophthalmic Epidemiol Date: 2018-05-02 Impact factor: 1.648